
Theratechnologies THTX
Geschäftsbericht 2024
hinzugefügt 11.04.2026
Theratechnologies EBITDA per Share 2011-2026 | THTX
EBITDA per Share Jährlich Theratechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -0.33 | -0.23 | -0.11 | -0.05 | -0.0918 | 0.068 | 0.071 | -0.144 | -0.0698 | -0.234 | -0.307 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 0.071 | -0.33 | -0.13 |
EBITDA per Share anderer Aktien in der Pharmaeinzelhändler
| Name | EBITDA per Share | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-8.81 | $ 8.64 | 8.07 % | $ 85.4 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.66 | -1.48 % | $ 8.81 B | ||
|
I-Mab
IMAB
|
0.08 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | ||
|
Applied Therapeutics
APLT
|
-0.77 | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
3.68 | $ 21.36 | 4.86 % | $ 998 M | ||
|
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
0.1 | $ 1.47 | 5.0 % | $ 378 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 2.92 | - | $ 4.81 M | ||
|
Aquestive Therapeutics
AQST
|
-0.66 | $ 4.19 | 2.7 % | $ 448 M | ||
|
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 24.12 | -0.37 % | $ 3.07 B | ||
|
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-4.28 | $ 32.59 | 1.09 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 1.47 | -1.34 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
-27.7 | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
0.74 | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.05 | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B | ||
|
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-0.67 | $ 4.25 | 8.35 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | ||
|
Esperion Therapeutics
ESPR
|
0.29 | $ 2.22 | 2.3 % | $ 461 M | ||
|
Evogene Ltd.
EVGN
|
-0.77 | $ 0.82 | 1.13 % | $ 27.9 M | ||
|
Baudax Bio
BXRX
|
-171 | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
-1.7 | $ 3.2 | 2.24 % | $ 322 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | ||
|
CymaBay Therapeutics
CBAY
|
-0.95 | - | - | $ 3.45 B | ||
|
Aileron Therapeutics
ALRN
|
-1.99 | - | 10.36 % | $ 9.8 M |